On September 8, 2020 Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, reported it has entered into an agreement with Health Net Federal Services LLC to be an in-network provider for its Target Selector liquid biopsy oncology platform for the TRICARE West (TriWest) region network (Press release, Biocept, SEP 8, 2020, View Source [SID1234564788]). TriWest provides healthcare services to approximately three million members of the U.S. military and their families.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It’s an honor to become a provider for TriWest and to support the healthcare needs of our country’s military service members and their families," said Michael Nall, President and CEO of Biocept. "Our Target Selector platform can be used to improve treatment outcomes by helping physicians rapidly obtain the actionable information they need to design personalized treatment plans for their patients diagnosed with cancer. Expanding the number of managed care agreements is among our strategic objectives. Our liquid biopsy platform is available on an in-network basis to millions of patients across the U.S. and now we are very proud to include those who are serving our country as they fight a new battle, this time with cancer."

About TRICARE West Region Network
TRICARE is the worldwide healthcare program available to eligible beneficiaries of the seven uniformed services – the Army, U.S. Navy, U.S. Air Force, U.S. Marine Corps, U.S. Coast Guard, Commissioned Corps of the U.S. Public Health Service, and the Commissioned Corps of the National Oceanic and Atmospheric Administration. TRICARE-eligible beneficiaries may include active duty service members and their families, retired service members and their families, National Guard and Reserve members and their families, survivors, certain former spouses, and others. TRICARE is jointly managed by the Defense Health Agency (DHA) and the TRICARE Health Plan. The DHA has partnered with civilian regional contractors in the East and West regions to assist TRICARE regional directors, and military hospital and clinic commanders in operating an integrated health care delivery system

TriWest is managed under a contract with the DHA by Health Net Federal Services. Coverage includes the states of Alaska, Arizona, California, Colorado, Hawaii, Idaho, Iowa (except the Rock Island Arsenal area), Kansas, Minnesota, Missouri (except the St. Louis area), Montana, Nebraska, Nevada, New Mexico, North Dakota, Oregon, South Dakota, Texas (areas of Western Texas only), Utah, Washington, and Wyoming. More information is available at www.tricare-west.com.

On September 8, 2020 Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, reported that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 million in the raise (Press release, Nanospectra Biosciences, SEP 8, 2020, View Source [SID1234564787]). The equity round was led by Sirtex Medical as a strategic investor with additional participation from existing and new investors. Sirtex is a leading U.S. based provider of targeted liver cancer therapies via their proprietary SIR-Spheres Y-90 microspheres with global operations. Kevin P. Smith, Sirtex’s General Counsel and Executive Vice President, Business Development, will join the Nanospectra Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AuroLase, Nanospectra’s lead product, is the first and only ultra-focal ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation and alternative focal therapies. Proceeds from the financing will be used to further develop AuroLase, including full completion of the ongoing pivotal study for prostate cancer tissue ablation, filing of a 510(k) with the U.S. Food and Drug Administration (FDA) for marketing clearance, and preparing for commercialization. In addition, Sirtex and Nanospectra have agreed to exclusively negotiate for a defined period of time for access to AuroLase in certain geographies outside of the U.S.

"We are thrilled to welcome Sirtex Medical as a strategic investor due to their shared commitment and understanding of the clinical and patient benefits of minimally-invasive oncology therapies," said David Jorden, CEO of Nanospectra. "With established global operational capabilities and distribution, they are well positioned to advise on our commercialization efforts in both the U.S. and other geographies. We look forward to Sirtex’s active engagement as we proceed with our clinical programs."

The AuroLase pivotal study for the focal ablation of prostate tissue via nanoparticle directed near infrared irradiation is approved by the FDA under the original Investigational Device Exemption (IDE) and follows the successful first-in-human pilot study that enrolled 46 subjects at three U.S. sites. The ongoing pivotal study will enroll up to 60 patients at up to eight clinical trial sites throughout the U.S. and the combined dataset from both studies will constitute the clinical package Nanospectra will submit to the FDA.

"Nanospectra’s AuroLase is a perfect complement to our technology approach and corporate strategic focus on minimally-invasive therapies," said Kevin R. Smith, CEO of Sirtex Medical. "We look forward to collaborating with Nanospectra to explore and develop innovative therapies to meet unmet medical needs in patients with various cancer conditions."

On September 8, 2020 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported its participation in the following conferences in September (Press release, I-Mab Biopharma, SEP 8, 2020, View Source [SID1234564786]). Details of the conferences and management presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Presentation: Tuesday, September 15, 2020 at 8:00-8:30 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

Webcast link: View Source

The webcast will also be available under "Event Calendar" on IMAB’s IR website at View Source

One-on-one meetings: September 15-17, 2020

For more information, please contact your Cantor Fitzgerald representative.

Jefferies Virtual Asia Forum
Presentation: Wednesday, September 16, 2020 at 4:00-4:50 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 14-16, 2020

For more information, please contact your Jefferies representative.

ICBCI Virtual ADR New Economy Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 18, 2020

For more information, please contact your ICBCI representative.

2020 Huatai USA Autumn Virtual China Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 21-23, 2020

For more information, please contact your Huatai representative.

Morgan Stanley Virtual Asia Pacific Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 24-25, 2020

For more information, please contact your Morgan Stanley representative.

On September 8, 2020 Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, reported that Ardelyx management will participate in three upcoming investor conferences in September including (Press release, Ardelyx, SEP 8, 2020, View Source [SID1234564785]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9th
22nd Annual H.C. Wainwright Global Investment Conference on Monday, September 14th with a presentation at 5:00 p.m. E.T.
Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday, September 17th with a presentation at 12:40 p.m. E.T.
Both the H.C. Wainwright and Cantor Fitzgerald conference presentations will be available via webcast. To access the live webcasts of Ardelyx’s presentations, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcasts will be available on the Ardelyx website for 30 days following each conference.

On September 8, 2020 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference (Press release, Lipocine, SEP 8, 2020, https://www.prnewswire.com/news-releases/lipocine-to-participate-in-hc-wainwright-annual-global-investment-conference-301124187.html [SID1234564784]). The conference will take place virtually September 14 – 16, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Date:

Monday, September 14

Time:

12 noon Eastern Time

Webcast:

View Source

To register in advance for the conference, refer to View Source